Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Objective To evaluate the efficacy and safety of secukinumab, a fully human, anti-interleukin (IL)-17A monoclonal antibody, in patients with psoriatic arthritis (PsA).Methods 42 patients with active PsA fulfilling ClASsification for Psoriatic ARthritis (CASPAR) criteria were randomly assigned (2:1) to receive two intravenous secukinumab doses (10 mg/kg; n=28) or placebo (n=14) 3 weeks apart. The primary endpoint was the proportion of American College of Rheumatology (ACR) 20 responses at week 6 for secukinumab versus placebo (one-sided p<0.1).Results Primary endpoint: ACR20 responses at week 6 were 39% (9/23) for secukinumab versus 23% (3/13) for placebo (p=0.27). ACR20 responses were greater with secukinumab versus placebo at week 12 (39% (9/23) vs 15% (2/13), p=0.13) and week 24 (43% (10/23) vs 18% (2/11), p= 0.14). At week 6, 'good' European League Against Rheumatism response was seen in 21.7% (5/23) secukinumab versus 9.1% (1/11) placebo patients. Compared with placebo at week 6, significant reductions were observed among secukinumab recipients for C reactive protein (p=0.039), erythrocyte sedimentation rate (p=0.038), Health Assessment Questionnaire Disability Index (p=0.002) and Short Form Health Survey (SF-36; p=0.030) scores. The overall adverse event (AE) frequency was comparable between secukinumab (26 (93%)) and placebo (11 (79%)) recipients. Six serious AEs (SAEs) were reported in four secukinumab patients and one SAE in one placebo patient.Conclusions Although the primary endpoint was not met, clinical responses, acute-phase reactant and quality of life improvements were greater with secukinumab versus placebo, suggesting some clinical benefit. Secukinumab exhibited satisfactory safety. Larger clinical trials of secukinumab in PsA are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“IL-17 blockade was effective in psoriatic arthritis (PsA) (McInnes et al., 2014; Mease and McInnes, 2016) as well as ankylosing spondylitis (AS)”
From The IL-17 Family of Cytokines in Health and Disease (2019) · cites this paper as McInnes et al., 2014
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
Measurement of patient outcome in arthritis
Fries, J. F., Spitz, P., Kraines, R. G., & Holman, H. R. (1980) · Arthritis & Rheumatism · doi:10.1002/art.1780230202 · Cited by 4,382
Taylor, W., Gladman, D., Helliwell, P., Marchesoni, A., Mease, P., & Mielants, H. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21972 · Cited by 3,746
American college of rheumatology preliminary definition of improvement in rheumatoid arthritis
Felson, D. T., Anderson, J. J., Boers, M., Bombardier, C., Furst, D., Goldsmith, C., Katz, L. M., Lightfoot, R., Paulus, H., Strand, V., et al. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380602 · Cited by 2,829
Severe Psoriasis – Oral Therapy with a New Retinoid
Fredriksson, T., & Pettersson, U. (2009) · Dermatologica · doi:10.1159/000250839 · Cited by 2,718
van Gestel, A. M., Prevoo, M. L. L., van't Hof, M. A., van Rijswijk, M. H., van de Putte, L. B. A., & van Riel, P. L. C. M. (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780390105 · Cited by 1,572
Psoriatic arthritis: epidemiology, clinical features, course, and outcome
Gladman, D. D., Antoni, C., Mease, P., Clegg, D. O., & Nash, P. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.032482 · Cited by 1,536
Phagocytosis of Apoptotic Neutrophils Regulates Granulopoiesis via IL-23 and IL-17
Stark, M. A., Huo, Y., Burcin, T. L., Morris, M. A., Olson, T. S., & Ley, K. (2005) · Immunity · doi:10.1016/j.immuni.2005.01.011 · Cited by 947
Mease, P. J., Gladman, D. D., Ritchlin, C. T., Ruderman, E. M., Steinfeld, S. D., Choy, E. H. S., Sharp, J. T., Ory, P. A., Perdok, R. J., & Weinberg, M. A. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21306 · Cited by 909
Research works printed but not linked: 2
- Raychaudhuri, 2012, IL-17 receptor and its functional significance in psoriatic arthritis, Mol Cell Biochem, 359, 419, 10.1007/s11010-011-1036-6 · DOI · Paper page
- Baeten, 2011, The anti-IL-17A monoclonal antibody secukinumab (AIN457) showed good safety and efficacy in the treatment of active ankylosing spondylitis, Ann Rheum Dis, 70, 127
Cited by
10 Years of GWAS Discovery: Biology, Function, and Translation
Visscher, P. M., Wray, N. R., Zhang, Q., Sklar, P., McCarthy, M. I., Brown, M. A., & Yang, J. (2017) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2017.06.005 · Cited by 3,719
The IL-17 Family of Cytokines in Health and Disease
McGeachy, M. J., Cua, D. J., & Gaffen, S. L. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.021 · Cited by 1,443
Ritchlin, C. T., Colbert, R. A., & Gladman, D. D. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1505557 · Cited by 1,404
Gossec, L., Smolen, J. S., Ramiro, S., de Wit, M., Cutolo, M., Dougados, M., Emery, P., Landewé, R., Oliver, S., Aletaha, D., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208337 · Cited by 920
Self-citationTeng, M. W. L., Bowman, E. P., McElwee, J. J., Smyth, M. J., Casanova, J.-L., Cooper, A. M., & Cua, D. J. (2015) · Nature Medicine · doi:10.1038/nm.3895 · Cited by 873
Metadata
- Authors
- McInnes, I. B., Sieper, J., Braun, J., Emery, P., van der Heijde, D., Isaacs, J. D., Dahmen, G., Wollenhaupt, J., Schulze-Koops, H., Kogan, J., Ma, S., Schumacher, M. M., Bertolino, A. P., Hueber, W., & Tak, P. P.
- Affiliations
- University of Glasgow (GB)
- Charité – Universitätsmedizin Berlin (DE)
- Rheumazentrum Ruhrgebiet (DE)
- University of Leeds (GB)
- Newcastle University (GB)
- Schön Klinik Hamburg Eilbek (DE)
- Novartis (Switzerland) (CH)
- Novartis (China) (CN)
- GlaxoSmithKline (United Kingdom) (GB)
- Corresponding author
- Hueber, Wolfgang
- Venue
- Annals of the Rheumatic Diseases
- Publisher
- Elsevier BV
- Published
- 2014-02
- Volume
- 73
- Issue
- 2
- Pages
- 349-356
- ISSN
- 0003-4967 (ISSN-L)
- OpenAlex
- W2151280501
- Cited by
- 343
- References
- 41
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 5 · 2023: 10 · 2022: 16 · 2021: 23 · 2020: 14 · 2019: 22 · 2018: 31 · 2017: 34 · 2016: 42 · 2015: 51 · 2014: 62
- FWCI
- 48.39
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- Annals of the Rheumatic Diseases (publishedVersion)
- PubMed (publishedVersion)
- The Novartis Repository (Novartis) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- National Institute for Health and Care Research (NF-SI-0508-10299)
- Versus Arthritis (18475)
- Topics
- Health Sciences › Medicine › Rheumatology › Spondyloarthritis Studies and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Keywords
- secukinumab, psoriatic arthritis, IL-17A, anti-IL-17A monoclonal antibody, biologic therapy, ACR20 response, disease activity, adverse events, treatment safety, CASPAR classification criteria, health-related quality of life, C-reactive protein, erythrocyte sedimentation rate
- MeSH terms
- Adult, Antibodies, Monoclonal, Blood Sedimentation, C-Reactive Protein, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Severity of Illness Index, Biomarkers, Arthritis, Psoriatic, Treatment Outcome, Antirheumatic Agents, Interleukin-17, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. https://app.cochat.ai/papers/10.1136/annrheumdis-2012-202646
- The paper
- McInnes, I. B., Sieper, J., Braun, J., Emery, P., van der Heijde, D., Isaacs, J. D., Dahmen, G., Wollenhaupt, J., Schulze-Koops, H., Kogan, J., Ma, S., Schumacher, M. M., Bertolino, A. P., Hueber, W., & Tak, P. P. (2014). Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2012-202646
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.